Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials with a site in Fuzhou

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Active, closed

A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06711900Non-Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Cisplatin·Carboplatin

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

432

Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou

2024-10-30

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

NCT06656390Advanced Cancer, Advanced Solid Tumors

Shanghai Allink Biotherapeutics Co., Ltd.

Phase 1/2

202

Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin

2024-10-24

Recruiting

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779Metastatic Castration-Resistant Prostate Cancer

DrugsMevrometostat·Xtandi·Enzalutamide

Pfizer

Phase 3

900

Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou

2024-10-22

Active, closed

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)

DrugsMevrometostat·Xtandi·Taxotere·Enzalutamide

Pfizer

Phase 3

609

Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan

2024-10-21

Recruiting

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

NCT06598800Advanced Solid Tumor

BeOne Medicines

Phase 1

153

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan

2024-10-18

Recruiting

Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

NCT06760273Bronchiectasis Adult

Shanghai Pulmonary Hospital, Shanghai, China

Observational

364

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning

2024-10-16

Recruiting

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

Boehringer Ingelheim

Phase 3

1,800

Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou

2024-10-14

Recruiting

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386Non-small Cell Lung Cancer

DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin

Bristol-Myers Squibb

Phase 3

1,000

Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou

2024-10-07

Recruiting

A Study of BG-C477 in Participants With Advanced Solid Tumors

NCT06596473Advanced Solid Tumors

DrugTislelizumab

BeOne Medicines

Phase 1

310

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou

2024-10-03

Not yet open

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

NCT06441045Leptomeningeal Metastasis

DrugPemetrexed

Fujian Cancer Hospital

Phase 2

112

Fuzhou

2024-10-01

Not yet open

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

NCT06600841Platinum-resistant Ovarian Cancer (PROC), Immunotherapy

DrugImmunotherapy: Adebrelimab

Fujian Cancer Hospital

Phase 2

Fuzhou

2024-10-01

By invitation

Facial Aesthetic Analysis Model Based on Clinical Cohort Phenotype to Explore 45° Facial Profile.

NCT06984666Malocclusion, Angle Class II, Malocclusion, Angle Class III

Linyu Xu

Not applicable

Fuzhou

2024-10-01

Not yet open

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

NCT06630871NMIBC

DrugTislelizumab

Fujian Medical University Union Hospital

Phase 2

Fuzhou

2024-10

Recruiting

Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)

NCT06602011Hepatocellular Carcinoma

Fujian Provincial Hospital

Observational

Fuzhou, Xiamen, Zhangzhou

2024-09-30

Recruiting

Neoadjuvant Triple Therapy for Resectable HCC

NCT06569498Resectable Hepatocellular Carcinoma

Fujian Provincial Hospital

Observational

Fuzhou, Xiamen, Zhangzhou

2024-09-30

Active, closed

A Study in Patients With Myasthenia Gravis in China

NCT06700616Myasthenia Gravis

AstraZeneca

Observational

1,199

Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan

2024-09-26

Recruiting

Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）

NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction

Capital Medical University

Phase 3

2,105

Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Shenzhen, Nanning

2024-09-23

Recruiting

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer

DrugsPatritumab deruxtecan·Xeloda·Sacituzumab tirumotecan·Leucovorin

Merck Sharp & Dohme LLC

Phase 1/2

160

Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou

2024-09-20

Recruiting

Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic

Sun Yat-sen University

Phase 3

252

Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai

2024-09-18

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai

2024-09-18

Active, closed

Analysis of Predictive Factors for Urinary Leakage After Partial Nephrectomy for Renal Hilum Tumors

NCT06916910Partial Nephrectomy, Renal Hilum Tumors, Urinary Leakage

First Affiliated Hospital of Fujian Medical University

Observational

200

Fuzhou

2024-09-18

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06589986Moderately to Severely Active Ulcerative Colitis

DrugAfimkibart

Hoffmann-La Roche

Phase 3

400

Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou

2024-09-17

Active, closed

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer

DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel

Amgen

Phase 1

Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing

2024-09-17

Recruiting

Transperineal Irreversible Electroporation for Benign Prostatic Hyperplasia

NCT06867315Benign Prostatic Hyperplasia

First Affiliated Hospital of Zhejiang University

Not applicable

Hefei, Fuzhou, Quanzhou, Xiamen, Zhangzhou, Shanghai, Hangzhou

2024-09-11

Recruiting

Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer

NCT06140589Cervical Cancer

DrugCadonilimab

Fujian Cancer Hospital

Observational

200

Fuzhou

2024-09-07

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai

2024-09-04

Recruiting

Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor

Axter Therapeutics (Beijing) Co., Ltd

Phase 1

Beijing, Changsha, Fuzhou, Guangzhou, Shanghai

2024-09-04

Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

NCT06554795Solid Tumor, Adult

DualityBio Inc.

Phase 1/2

360

Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang

2024-09-03

Recruiting

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

NCT07551037Acute Myeloid Leukemia, Personalized Active Immunotherapy, Maintenance Therapy

Fujian Medical University Union Hospital

Phase 1

Fuzhou

2024-09-01

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

444

Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha

2024-08-28

Active, closed

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

NCT06502977Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 2

Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin

2024-08-27

Active, closed

A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

NCT06610526Chronic Kidney Disease

DrugDapagliflozin

AstraZeneca

Phase 4

731

Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin

2024-08-23

Recruiting

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy

DrugsRiliprubart·IVIG

Sanofi

Phase 3

160

Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Jiazhuang, Jinan, Nanchang

2024-08-21

Recruiting

Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)

NCT06534723Alzheimer's Dementia

Sichuan Jishengtang Pharmaceutical Co., Ltd.

Phase 3

570

Fuzhou

2024-08-20

Recruiting

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

NCT07122414Non-muscle Invasive Bladder Cancer (NMIBC)

DrugFL115

Suzhou Forlong Biotechnology Co., Ltd

Phase 1/2

Beijing, Fuzhou, Wenzhou, Changsha, Nanjing, Suzhou, Qingdao, Chengdu

2024-08-16

Recruiting

Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

NCT06561399Hepatocellular Carcinoma Non-resectable

Fujian Provincial Hospital

Observational

Fuzhou

2024-08-15

Active, closed

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT06508658Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin

Genmab

Phase 3

379

Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou

2024-08-12

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2024-08-07

Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer

DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel

Merck Sharp & Dohme LLC

Phase 1/2

210

Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou

2024-08-07

Recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer

DrugsJAB-3312·Glecirasib·Pemetrexed·Tislelizumab

Allist Pharmaceuticals, Inc.

Phase 3

392

Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin

2024-08-07

Recruiting

A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

NCT06487455Advanced Solid Tumor

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1

170

Changsha, Fuzhou, Hangzhou, Kunming, Shanghai, Wuhan

2024-08-06

Recruiting

A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

NCT06496490Non-Small Cell Lung Cancer

DrugsTQB2102·Benmelstobart

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 2

270

Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin

2024-08-06

Recruiting

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

NCT06421142Urinary Bladder Neoplasms

First Affiliated Hospital of Fujian Medical University

Not applicable

Fuzhou

2024-08-02

Recruiting

68Ga-NI-FAPI PET/CT: First-in-human Study

NCT06688305Malignant Neoplasm

Drug68Ga-NI-FAPI

First Affiliated Hospital of Fujian Medical University

Early Phase 1

Fuzhou

2024-08-01

By invitation

The Construction and Application of a Mobile Health Management Program for Elderly Depression Based on the Patterns of Cognitive Function Changes

NCT06709027Patients With Depression in the Elderly

Fujian Medical University

Not applicable

Fuzhou

2024-08-01

Active, closed

Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning

NCT07332923Renal Clear Cell Carcinoma, HIF-2α, Radiomics, Nomogram

First Affiliated Hospital of Fujian Medical University

Observational

500

Fuzhou

2024-08-01

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou

2024-08-01

Active, closed

Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke

NCT06360458Acute Ischemic Stroke, Large Infarct Core

DrugMethylprednisolone sodium succinate

Wan-Jin Chen

Phase 3

928

Hefei, Taihe Chengguanzhen, Wuhu, Anxi, Fuqing, Fuzhou, Longyan, Nanping

2024-08-01

Recruiting

THBC/CGF for Alveolar Bone Regeneration: A Real-World Study

NCT07779421Alveolar Bone Loss, Alveolar Ridge Resorption After Extraction, Tooth, Impacted

Stomatological Hospital Affiliated with Fujian Medical University

Not applicable

136

Fuzhou

2024-08-01

Not yet open

Electroacupuncture Treatment of Behavioral and Psycological Symptoms in Patients With Alzheimer's Disease

NCT06523309BPSD (Behavioral and Psycological Symptoms of Dementia), Alzheimer's Dementia

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Observational

1,000

Beijing, Fuzhou, Harbin

2024-07-30

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning

2024-07-24

Recruiting

PulseSelect™ PFA Global Registry

NCT06393920Atrial Fibrillation

Medtronic Cardiac Ablation Solutions

Observational

1,950

Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, Ürümqi

2024-07-23

Recruiting

Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock

NCT06351150Vasodilatory Shock

DrugAngiotensin II

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

214

Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan

2024-07-23

Recruiting

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors

DrugsTislelizumab·Bevacizumab

BeOne Medicines

Phase 1/2

630

Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan

2024-07-23

Recruiting

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

NCT06431490Biliary Tract Cancer

DrugTQB2102

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1/2

102

Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen

2024-07-22

Not yet open

Electroacupuncture for the Treatment of Agitated Symptoms of Alzheimer's Disease

NCT06495957Agitation Associated With Alzheimer's Dementia, Alzheimer's Dementia

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Not applicable

224

Beijing, Fuzhou, Harbin

2024-07-20

Recruiting

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

NCT06434597Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

DrugSPH5030

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 2

Beijing, Changsha, Changzhi, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei

2024-07-17

Active, closed

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580Generalized Myasthenia Gravis

DrugTelitacicept

Vor Biopharma

Phase 3

191

Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan

2024-07-17

Recruiting

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

NCT06413654Neuromyelitis Optica Spectrum Disorders

DrugB001

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2/3

132

Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou

2024-07-17

Recruiting

Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy

NCT06559696Breast Cancer

Fujian Medical University Union Hospital

Phase 3

722

Fuzhou

2024-07-15

Recruiting

A Clinical Study of B007 in the Treatment of Pemphigus.

NCT06454357Pemphigus

DrugB007

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2/3

132

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai

2024-07-12

Active, closed

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic

DrugRiliprubart

Sanofi

Phase 3

109

Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang

2024-07-12

Recruiting

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

NCT06601309Esophageal Squamous Cell Carcinoma

DrugsSerplulimab·Paclitaxel·Cisplatin

Fujian Medical University Union Hospital

Phase 2

Fuzhou

2024-07-11

Recruiting

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

NCT06434610Platinum-resistant Recurrent Ovarian Cancer

DrugPaclitaxel

Shanghai Jiaolian Drug Research and Development Co., Ltd

Phase 2

Beijing, Bengbu, Changsha, Fuzhou, Guangzhou, Jinan, Kunming, Nanning

2024-07-11

Active, closed

Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction

NCT06372925Plaque, Atherosclerotic

DrugsInclisiran·Atorvastatin

Novartis Pharmaceuticals

Phase 4

318

Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan

2024-07-09

Recruiting

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

NCT06235203Recurrent Nasopharyngeal Carcinoma

Eye & ENT Hospital of Fudan University

Phase 3

154

Shanghai, Fuzhou, Nanning, Shenzhen

2024-07-09

Recruiting

A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT07923214Advanced Solid Tumors, Breast Cancer, Ovarian Cancer, Gastric Cancer

Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.

Phase 1

Fuzhou, Dalian, Shanghai, Chengdu

2024-07-02

Recruiting

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

NCT06643208Intrahepatic Cholangiocarcinoma

Fujian Provincial Hospital

Observational

Fuzhou

2024-07-01

Not yet open

Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

NCT06475599Endometrial Cancer

DrugsAnlotinib hydrochloride·Benmelstobart

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

420

Hefei, Fuzhou, Lanzhou, Guangzhou, Huizhou, Jiangmen, Meizhou, Guigang

2024-07

Active, closed

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

DrugsIBI343·Irinotecan·Paclitaxel

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

464

Bengbu, Hefei, Lu'an, Wuhu, Beijing, Fuzhou, Lanzhou, Dongguan

2024-06-30

Recruiting

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

NCT06228079Recurrent Nasopharyngeal Carcinoma

Eye & ENT Hospital of Fudan University

Phase 3

176

Shanghai, Fuzhou, Nanning, Shenzhen

2024-06-25

Recruiting

Personalized Interventions Via Health Portraits in Mild Behavioral Impairment

NCT06416514Neurocognitive Disorders

Fujian Provincial Hospital

Not applicable

Fuzhou

2024-06-25

Recruiting

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

NCT06536400Solid Tumors

DrugHSK42360

Haisco Pharmaceutical Group Co., Ltd.

Phase 1

316

Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai

2024-06-25

Recruiting

18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study

NCT06734572Malignant Neoplasm

First Affiliated Hospital of Fujian Medical University

Early Phase 1

Fuzhou

2024-06-25

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR

AstraZeneca

Observational

1,850

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guiyang, Shijiazhuang

2024-06-25

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Cangzhou, Shijiazhuang, Harbin

2024-06-25

Active, closed

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT06378177Head and Neck Squamous Cell Carcinoma

DrugsToripalimab·Paclitaxel

Lyvgen Biopharma Holdings Limited

Phase 2

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha

2024-06-21

Recruiting

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

DrugsSacituzumab tirumotecan·Fluorouracil·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

220

Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu

2024-06-20

Recruiting

Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

NCT06791083Gastric Cancer

DrugsEnvafolimab·Fruquintinib

First Affiliated Hospital of Fujian Medical University

Phase 2

Fuzhou

2024-06-20

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou

2024-06-19

Recruiting

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

NCT07584954Solid Tumor Cancer, Solid Tumor Cancer Treatment With Immunotherapy

Jun Zhou

Phase 1

Fuzhou, Anyang, Jinan, Shanghai

2024-06-18

Recruiting

AMT-676 in Patients With Advanced Solid Tumors

NCT06400485Advanced Solid Tumors

DrugAMT-676

Multitude Therapeutics Inc.

Early Phase 1

Fuzhou, Guangzhou, Shanghai, Chengdu, Hangzhou

2024-06-18

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754Non-small Cell Lung Cancer (NSCLC)

DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

550

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin

2024-06-11

Active, closed

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

NCT06419621Triple Negative Breast Cancer(TNBC)

DrugsPumitamig·Nab-paclitaxel

Biotheus Inc.

Phase 3

392

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou

2024-06-11

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143Non-small Cell Lung Cancer, NSCLC

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

851

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan

2024-06-10

Active, closed

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

DrugsTarlatamab·Durvalumab

Amgen

Phase 3

563

Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou

2024-06-05

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou

2024-06-05

Recruiting

Impact of the Digital Multi-domain Cognitive Intervention in High-risk Populations for Dementia

NCT06442943Cognitive Dysfunction

Fujian Provincial Hospital

Not applicable

128

Fuzhou

2024-06-04

Recruiting

A Clinical Study of YL205 in Patients With Advanced Solid Tumors

NCT06459973Advanced Solid Tumors

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

252

Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin, Anyang, Zhengzhou

2024-06-04

Not yet open

Henagliflozin's Impact on Prediabetes Remission

NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders

DrugHenagliflozin

Shandong Provincial Hospital

Phase 4

984

Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen

2024-06

Active, closed

Effect of Preoperative Individualized Education on Anxiety and Recovery.

NCT06419088Education

Fujian Medical University Union Hospital

Not applicable

156

Fuzhou

2024-05-30

Recruiting

Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases

NCT06520774Aortic Arch Aneurysm, Penetrating Aortic Ulcer

Lifetech Scientific (Shenzhen) Co., Ltd.

Not applicable

103

Beijing, Changsha, Chengdu, Fuzhou, Hanzhou, Kunming, Nanjing, Shanghai

2024-05-30

Recruiting

Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma

NCT06445088Nasopharyngeal Carcinoma

Sun Yat-sen University

Observational

908

Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou

2024-05-29

Active, closed

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

DrugsAnvumetostat·Modified FOLFIRINOX·Cetuximab·Nab-paclitaxel

Amgen

Phase 1

120

Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changchun

2024-05-29

Recruiting

A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

NCT06387082Hematological Malignancies

Hutchmed

Phase 1

132

Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan

2024-05-27

Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729Non-small Cell Lung Cancer

DrugsCalderasib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

348

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi

2024-05-24

Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

NCT06375044Relapsed or Refractory Multiple Myeloma

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

130

Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou

2024-05-24

Recruiting

Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

NCT06607419B-Cell Lymphoblastic Leukemia

DrugBlinatumomab

Shanghai Jiao Tong University School of Medicine

Phase 2/3

Hefei, Fuzhou, Shanghai, Ningbo

2024-05-21

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang

2024-05-19

Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06415669Gastric/Gastroesophageal Junction Adenocarcinoma

DrugsApatinib Mesylate·Adebrelimab·Paclitaxel

The First Affiliated Hospital of Xiamen University

Phase 2

Fuzhou

2024-05-19

Recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

NCT06378138Hematologic Malignancies

DrugsICP-248·Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2/3

226

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou

2024-05-15

Recruiting

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

NCT07234162Peripheral T-cell Lymphoma

DrugsGolidocitinib·Chidamide·Gemcitabine

Dizal Pharmaceuticals

Phase 3

218

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning

2024-05-13

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan

2024-05-08

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

NCT06361888Metastatic Pancreatic Cancer

DrugsSurufatinib·Nab-paclitaxel·Gemcitabine

Hutchmed

Phase 2/3

502

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Nanning, Guandong

2024-05-08

Recruiting

AMT-116 in Patients with Solid Tumors

NCT06782334Advanced Solid Tumors

DrugAMT-116

Multitude Therapeutics Inc.

Phase 1/2

144

Fuzhou, Dongguan, Guangzhou, Nanning, Changsha, Hangzhou, Wenzhou

2024-05-07

Recruiting

Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection

NCT06406816Intrahepatic Cholangiocarcinoma

Yongyi Zeng

Early Phase 1

Fuzhou

2024-05-06

Active, closed

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT06356311Gastroesophageal Cancer

DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

473

Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang

2024-05-03

Recruiting

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

NCT06592417Advanced Malignant Solid Tumor

DrugJSKN016

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1

140

Fuzhou, Guangzhou

2024-04-30

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Beijing, Bengbu, Changsha, Chengdu, Foshan, Fuzhou, Guangdong, Haikou

2024-04-29

Recruiting

Cognitive Leisure and Preclinical Alzheimer's Disease: Exploring Neural Mechanisms

NCT06215274Cognitive Dysfunction

Yuanjiao Yan

Observational

156

Fuzhou

2024-04-27

Recruiting

A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

NCT06387069Acute Myeloid Leukemia

DrugHMPL-306

Hutchmed

Phase 3

316

Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou

2024-04-26

Active, closed

Evolve China PMCF Study

NCT06368622Intracranial Aneurysm

Stryker Neurovascular

Observational

500

Beijing, Changchun, Fuzhou, Guangzhou, Kunming, Nanyang, Ningbo, Qingdao

2024-04-24

Recruiting

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

NCT06349317Hepatocellular Carcinoma

Yongyi Zeng

Phase 2

Fuzhou

2024-04-22

Recruiting

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

NCT06319820Non-Muscle Invasive Bladder Neoplasms

DrugGemcitabine

Janssen Research & Development, LLC

Phase 3

641

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

2024-04-18

Active, closed

A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors

NCT07104877Colorectal Cancer, Gastric Cancer (GC), Gastrointestinal Tumors

DrugsSYH2051·SYS6010

Fujian Cancer Hospital

Not applicable

Fuzhou

2024-04-18

Active, closed

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

NCT06394414Advanced Solid Tumors

DrugsTam-Peli·Serplulimab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

187

Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin

2024-04-17

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot

2024-04-16

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Beijing, Changchun, Chongqing, Fuzhou, Guangxi, Guangzhou, Guiyang, Ningbo

2024-04-16

Recruiting

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

NCT06363825Advanced Hepatocellular Carcinoma

DrugsApatinib·Camrelizumab

Fujian Medical University

Phase 2

Fuzhou

2024-04-12

Recruiting

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

NCT06233942Advanced Solid Tumor

DrugsTislelizumab·Bevacizumab

BeOne Medicines

Phase 1

308

Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan

2024-04-12

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2024-04-11

Recruiting

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

NCT06510660Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers

DrugAdebrelimab

Fujian Medical University Union Hospital

Phase 2

Fuzhou

2024-04-11

Recruiting

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137Non Small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

780

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Suzhou

2024-04-03

Recruiting

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

NCT06241781Adult

DrugsGT101·Gemcitabine

Grit Biotechnology

Phase 2

Beijing, Fuzhou, Shenzhen, Guilin, Ha’erbin, Luoyang, Zhengzhou, Wuhan

2024-04-02

Recruiting

pBFS Guided rTMS Over Cognitive Control Network for ASD

NCT06255535Autism Spectrum Disorder

Changping Laboratory

Not applicable

215

Fuzhou, Baoding, Xi'an, Jining, Linyi

2024-04-01

Recruiting

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

NCT06280105Hepatocellular Carcinoma

DrugsRegorafenib·Cadonilimab

Meng Chao Hepatobiliary Hospital of Fujian Medical University

Phase 2

Fuzhou

2024-03-31

Recruiting

Goal-directed Enteral Nutritional Perioperative Management

NCT06510543Esophagus Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not applicable

400

Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan

2024-03-30

Recruiting

Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)

NCT06284642Aneurysmal Subarachnoid Hemorrhage

DrugUrokinase

Second Affiliated Hospital of Nanchang University

Phase 4

424

Hefei, Heihe, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha

2024-03-28

Recruiting

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

NCT06300177Non Small Cell Lung Cancer

DrugsD-1553·Docetaxel

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

522

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang

2024-03-28

Active, closed

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer

Acerand Therapeutics (Shanghai) Limited

Phase 1/2

298

Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan

2024-03-22

Recruiting

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

NCT06463834Esophageal Squamous Cell Carcinoma

DrugSintilimab

Fujian Cancer Hospital

Phase 2

Fuzhou

2024-03-20

Recruiting

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

NCT06314334Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

DrugsGelad·P-GemOx·Pegaspargase·Sintilimab

Fudan University

Phase 2

210

Fuzhou, Nantong, Shanghai, Hangzhou, Ningbo

2024-03-04

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei

2024-03-04

Recruiting

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

NCT06239727Nasopharyngeal Carcinoma

DrugsCamrelizumab·Capecitabine·Gemcitabine·Cisplatin

Sun Yat-sen University

Phase 3

593

Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning

2024-03-01

Recruiting

68Ga-FAPI-Biotin PET/CT in Patients With Various Types of Cancer

NCT06740240Tumor

First Affiliated Hospital of Fujian Medical University

Early Phase 1

Fuzhou

2024-03-01

Recruiting

68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies

NCT06438250Malignant Neoplasm

First Affiliated Hospital of Fujian Medical University

Early Phase 1

Fuzhou

2024-03-01

Recruiting

Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery

NCT06254859Thyroid Cancer, Thyroid Cancer, Papillary

Fujian Medical University

Observational

100

Fuzhou

2024-03-01

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Xi’an, Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning

2024-02-27

Active, closed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

NCT06225804Non-Small Cell Lung Cancer

Abbisko Therapeutics Co, Ltd

Phase 1

164

Hefei, Fuzhou, Xi'an, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang

2024-02-22

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Hefei, Fuzhou, Foshan, Guangzhou, Jiangmen, Nanning, Luoyang, Zhengzhou

2024-02-21

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou

2024-02-20

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou

2024-02-09

Recruiting

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

NCT06112704Advanced Solid Tumor

DrugRis-Rez

Hansoh BioMedical R&D Company

Phase 2

220

Hefei, Fujian, Fuzhou, Guangzhou, Harbin, Anyang, Luoyang, Nanyang

2024-02-06

Active, closed

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

NCT06198751Breast Cancer

DrugTQB2102

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

104

Chongqing, Fuzhou, Guiyang, Harbin, Changsha, Shenyang, Shanghai

2024-02-05

Recruiting

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

NCT06243354Safety, Tolerability, Efficacy

Sichuan Huiyu Pharmaceutical Co., Ltd

Phase 1/2

257

Fuzhou, Changsha, Shenyang, Jinan, Shanghai, Chengdu

2024-02-04

Recruiting

High-Strength Suture vs. Traditional Tension Band for Patellar Fractures

NCT07248982Patella Fracture

Fuzhou University Affiliated Provincial Hospital

Observational

Fuzhou

2024-02-01

Recruiting

Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis

NCT06307314Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker

Nanfang Hospital, Southern Medical University

Observational

300

Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou

2024-02-01

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

NCT05956587Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

DrugsSI-B003·Iza-bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2

121

Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha

2024-01-29

Active, closed

A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

NCT06265428HER2-positive Breast Cancer

DrugsDB-1303/BNT323·Trastuzumab emtansine

DualityBio Inc.

Phase 3

228

Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou

2024-01-29

Recruiting

Driving Pressure-guided Lung Protective Ventilation

NCT06361420Hypoxemia, Ventilator Lung

Yong Lin, PhD

Not applicable

Fuzhou

2024-01-26

Recruiting

A Clinical Study of T3011 in Subjects With Advanced Melanoma

NCT06214156Advanced Melanoma

DrugT3011

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1/2

Beijing, Bengbu, Changchun, Chengdu, Fuzhou, Zhengzhou, Zhongshan

2024-01-26

Active, closed

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891Chronic Graft Versus Host Disease

DrugsBelumosudil·Prednisolone·Prednisone

Sanofi

Phase 3

260

Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan

2024-01-23

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot

2024-01-22

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou

2024-01-18

Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer

DrugTrastuzumab deruxtecan

Daiichi Sankyo

Observational

800

Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou

2024-01-15

Active, closed

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931Transthyretin Amyloid Cardiomyopathy

DrugCliramitug

Alexion Pharmaceuticals, Inc.

Phase 3

1,182

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou

2024-01-11

Recruiting

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

NCT06214143Advanced Solid Tumors

DrugT3011

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1/2

Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou

2024-01-11

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China

NCT05821855Open-angle Glaucoma, OAG

AbbVie

Phase 4

120

Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Wuhan, Qingdao, Chengdu

2024-01-09

Recruiting

Fuzhou Aging Brain Health Initiative

NCT07891429Dementia, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)

Fujian Medical University Union Hospital

Observational

3,000

Fushun, Fuzhou

2024-01-01

Recruiting

BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease

NCT06881420Acute Ischemic Stroke, ICAS - Intracranial Atherosclerosis

Fujian Medical University Union Hospital

Observational

500

Fuzhou

2024-01-01

Recruiting

Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes

NCT06977906Robotic-Assisted Radical Prostatectomy, Locally Advanced Prostate Cancer, Bladder Suspension

First Affiliated Hospital of Fujian Medical University

Not applicable

300

Fuzhou

2024-01-01

Not yet open

MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy

NCT06197126Cervical Cancer, Radiotherapy, Prognostic Model, MRI

Fujian Cancer Hospital

Observational

200

Fuzhou

2024-01-01

Not yet open

MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer

NCT06126393Endometrial Neoplasms

Fujian Cancer Hospital

Observational

350

Fuzhou

2024-01-01

Recruiting

Integrated Digital and Neurogenic Exosome Biomarkers for Early Diagnosis of Parkinson's Disease: Development and Application

NCT07679256PARKINSON DISEASE (Disorder)

Fujian Medical University Union Hospital

Observational

700

Fuzhou

2024-01-01

Not yet open

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

NCT06095167Nasopharyngeal Carcinoma

Fujian Cancer Hospital

Phase 3

476

Fuzhou

2024-01-01

Recruiting

Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

NCT06282796Breast Cancer

First Hospital of China Medical University

Observational

600

Fuzhou, Dalian, Shenyang, Chengdu

2024-01-01

Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624Prostate Cancer Metastatic

DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone

Merck Sharp & Dohme LLC

Phase 3

1,310

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha

2023-12-31

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Jiazhuang

2023-12-27

By invitation

Chemotherapy-immunotherapy-based Split-course Adaptive Hypofractionated Radiotherapy for Extensive-stage SCLC

NCT06816966Small-cell Lung Cancer

Fujian Medical University Union Hospital

Phase 2

Fuzhou

2023-12-26

Recruiting

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

NCT06406205Lupus Nephritis

Qilu Pharmaceutical Co., Ltd.

Phase 3

270

Bengbu, Bozhou, Hefei, Beijing, Fuzhou, Dalian, Shanghai, Changzhi

2023-12-25

Recruiting

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

NCT06181032Biliary Tract Malignancies

DrugsApatinib·Adebrelimab·Gemcitabine·Cisplatin

First Affiliated Hospital of Fujian Medical University

Phase 1

Fuzhou

2023-12-23

Recruiting

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

NCT06139575Prostate Cancer

Bivision Pharmaceuticals, Inc.

Phase 1/2

Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi

2023-12-22

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Haikou

2023-12-21

Recruiting

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 3

400

Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Nanning, Zhengzhou, Wuhan

2023-12-20

Recruiting

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer

DrugHS-20089

Hansoh BioMedical R&D Company

Phase 2

460

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang

2023-12-18

Recruiting

ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

NCT06007729Head and Neck Squamous Cell Carcinoma

DrugRis-Rez

Hansoh BioMedical R&D Company

Phase 2

170

Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou

2023-12-18

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing

2023-12-18

Recruiting

A Study of YL202 in Selected Patients With Advanced Solid Tumors

NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors

DrugYL202 should be infused

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2

200

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin

2023-12-15

Not yet open

Two Domestic HPV Vaccines and Imported HPV Vaccines in Women Aged 13-14 Years Study on Immunogenicity

NCT06137352HPV Infection, HPV Vaccine, Cervical Cancer Prevention

Fujian Maternity and Child Health Hospital

Observational

3,000

Fuzhou

2023-12-15

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788Non-small Cell Lung Cancer (NSCLC)

DrugsSacituzumab tirumotecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin

2023-12-15

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou

2023-12-14

Active, closed

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473Multiple Sclerosis

DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab

Sanofi

Phase 3

1,655

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou

2023-12-13

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin

2023-12-11

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130Advanced Solid Tumor

Eikon Therapeutics

Phase 1/2

156

Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai

2023-12-11

Recruiting

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

NCT06157827Advanced Neuroendocrine Carcinoma

DrugsLBL-024·Etoposide·Atezolizumab·Cisplatin

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

178

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang

2023-12-08

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, Ürümqi

2023-12-07

Active, closed

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT06132958Endometrial Cancer

DrugsAbraxane·Adriamycin·Sacituzumab tirumotecan·Taxol

Merck Sharp & Dohme LLC

Phase 3

710

Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning

2023-12-06

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Beijing, Changchun, Changsha, Chengdu, Deyang, Fuzhou, Guangzhou, Guiyang

2023-12-04

Not yet open

Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

NCT05965388HBV, HCC

DrugInterferon

Wen-hong Zhang

Observational

5,000

Hefei, Fuzhou, Wuhan, Nanjing, Xuzhou, Jinan, Taiyuan, Xi’an

2023-12-01

Recruiting

Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver Metastases

NCT07898904Gastroenteropancreatic Neuroendocrine Tumors

First Affiliated Hospital of Fujian Medical University

Observational

Fuzhou

2023-12-01

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer

DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant

BeOne Medicines

Phase 1

433

Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai

2023-12-01

Recruiting

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers

DrugXNW28012

Evopoint Biosciences Inc.

Phase 1/2

350

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin

2023-12-01

Not yet open

A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy

NCT06101966Cervical Cancer, Radiotherapy, Distant Metastasis, Prognostic Model

Fujian Cancer Hospital

Observational

500

Fuzhou

2023-12-01

By invitation

A Clinical Study of Non-curative Resection Plus Radiotherapy After Endoscopic ESD for Superficial Esophageal Squamous Cell Carcinoma

NCT06160557Esophagus Cancer, Radiotherapy, Endoscopic Mucosal Resection

Xiaomeng Zheng

Observational

Fuzhou

2023-11-29

Recruiting

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

NCT06155383Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsJS001·Disitamab Vedotin·Toripalimab·Capecitabine

RemeGen Co., Ltd.

Phase 2

Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou

2023-11-27

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou

2023-11-23

Recruiting

Research on the Development and Clinical Evaluation of Biomimetic Abutments

NCT06870955Tooth Loss

Stomatological Hospital Affiliated with Fujian Medical University

Not applicable

Fuzhou

2023-11-23

Active, closed

Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

NCT06057571Cholangiocarcinoma Metastatic

DrugTinengotinib

TransThera Sciences (Nanjing), Inc.

Phase 2

Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou

2023-11-17

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsSotorasib·Pembrolizumab

Amgen

Phase 3

750

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou

2023-11-16

Not yet open

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

NCT05990127Locally Advanced or Metastatic NSCLC

DrugsCadonilimab·Pemetrexed·Tislelizumab·Paclitaxel

Akeso

Phase 3

642

Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou

2023-11-14

Active, closed

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT06074588Non-small Cell Lung Cancer (NSCLC)

DrugsTaxotere·Sacituzumab tirumotecan·Pemetrexed·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

556

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin

2023-11-12

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang

2023-11-11

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha

2023-11-08

Recruiting

Prospective Cohort of Patients With Intracerebral Hemorrhage

NCT06670456Stroke, Acute, Intracerebral Hemorrhage

De-zhi Kang

Observational

3,000

Fuzhou, Quanzhou, Xiamen, Zhangzhou, Liaocheng

2023-11-06

By invitation

A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis

NCT06686082Subclinical Psoriatic Arthritis

Chao Ji

Observational

150

Fuzhou

2023-11-01

Recruiting

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

NCT06008288KRAS P.G12C, Pancreatic Cancer, Solid Tumor

DrugGlecirasib

Allist Pharmaceuticals, Inc.

Phase 2

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2023-10-27

Active, closed

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Yangzhou, Tongzhou, Fuzhou, Lanzhou, Guangzhou, Nanning, Haikou, Shijiazhuang

2023-10-26

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou

2023-10-25

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2023-10-24

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

NCT06084936Lymphoma

DrugsGlofitamab·Bendamustine·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 3

182

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai

2023-10-22

Recruiting

A Study of IBI363 in Subjects With Advanced Melanoma

NCT06081920Melanoma

DrugLenvatinib

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

180

Beijing, Fuzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Changchun, Jinan

2023-10-19

Recruiting

Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

NCT05991908Acute Myeloid Leukemia, Myelodysplastic Syndromes

Shanghai Jiao Tong University School of Medicine

Phase 3

222

Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming

2023-10-19

Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

NCT05944224Advanced Solid Tumors

DrugsSPH4336·Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 1/2

Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yongzhou, Shenzhen, Xi’an

2023-10-17

Recruiting

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037Lung Transplant Rejection

DrugsBelumosudil·Azithromycin

Sanofi

Phase 3

180

Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi

2023-10-10

Recruiting

Effects of Different Continuous Renal Replacement Therapy Patterns on Ionized Calcium in Patients With Citrate Anticoagulants Using Calcium-containing Replacement Solutions

NCT06021080Renal Injury, Regional Citrate Anticoagulation, Continuous Renal Replacement Therapy

Fujian Provincial Hospital

Observational

Fuzhou

2023-10-09

Recruiting

CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection

NCT06560827HCC

CARsgen Therapeutics Co., Ltd.

Phase 1

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai

2023-10-08

Not yet open

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST

NCT05970900Gastrointestinal Stromal Tumor of Rectum

DrugImatinib

Fujian Medical University Union Hospital

Phase 3

Fuzhou

2023-10-01

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

Beijing, Changde, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou

2023-09-22

Active, closed

A Study YL201 in Patients With Selected Advanced Solid Tumors

NCT06057922Advanced Solid Tumor

DrugTam-Peli

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

990

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou

2023-09-22

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangdong Province Guangzhou City, Guangzhou

2023-09-18

Recruiting

A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

NCT06016062Solid Tumor

DrugRC148

RemeGen Co., Ltd.

Phase 1/2

221

Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2023-09-14

Recruiting

Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

NCT06569524Non-alcoholic Steatohepatitis

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 2

120

Lu'an, Beijing, Fuzhou, Xiamen, Wuwei, Shenzhen, Liuzhou, Yulin

2023-09-14

Active, closed

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886Hepatocellular Carcinoma

DrugsTiragolumab·Tecentriq·Avastin·Atezolizumab

Hoffmann-La Roche

Phase 3

687

Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou

2023-09-14

Recruiting

Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery

NCT06030804Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors

DrugDexmedetomidine

Peking University First Hospital

Not applicable

4,532

Hefei, Beijing, Chongqing, Fuzhou, Jinjiang, Guangzhou, Shenzhen, Nanning

2023-09-12

Active, closed

An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS

NCT06454682Amyotrophic Lateral Sclerosis

DrugRJK002

RJK Biopharma Ltd

Early Phase 1

Fuzhou

2023-09-11

Recruiting

AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

NCT06035250Gastric Cancer, Image, Pathology

Chinese Academy of Sciences

Observational

200

Beijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai

2023-09-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

NCT05894239Metastatic Breast Cancer

DrugsPhesgo·Inavolisib

Hoffmann-La Roche

Phase 3

230

Baoding, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan

2023-09-08

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei

2023-09-07

Not yet open

Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer

NCT05730595Colorectal Neoplasms, Fluorescence, Lymph Node Excision

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not applicable

550

Hefei, Beijing, Chengdu, Fuzhou, Guangzhou, Shijiazhuang, Haerbin, Nanjing

2023-09-01

Recruiting

Personalized Optimization of Systematic Prostate Biopsy

NCT05998278Prostate Adenocarcinoma

Fujian Medical University Union Hospital

Not applicable

330

Fuzhou

2023-08-23

Recruiting

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

NCT06975618PIK3CA-Related Overgrowth Spectrum (PROS), PIK3CA-related Vascular Malformations (PRVM)

DrugCYH33

Haihe Biopharma Co., Ltd.

Phase 1/2

141

Beijing, Fuzhou, Guangzhou, Zhengzhou, Changsha, Shanghai, Chengdu

2023-08-22

Active, closed

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

NCT05995964Atopic Dermatitis

DrugTilrekimig

Pfizer

Phase 2

507

Beijing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Changsha, Wuhan, Nanchang

2023-08-22

Active, closed

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

NCT04586660Giant Cell Tumor of Bone

DrugsXgeva·Denosumab

Amgen

Phase 4

Beijing, Fuzhou, Guangzhou, Harbin, Xi'an, Hangzhou

2023-08-17

Recruiting

Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer

NCT06035679Breast Cancer Female

Youzhi Zhu

Not applicable

Fuzhou

2023-08-17

Recruiting

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

NCT05914116Advanced Solid Tumors

DrugsBNT324·Abiraterone·Itraconazole·Enzalutamide

DualityBio Inc.

Phase 1/2

862

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin

2023-08-17

Active, closed

Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)

NCT06577792Non Small Cell Lung Cancer

Sun Yat-sen University

Not applicable

620

Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing

2023-08-16

Not yet open

Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer

NCT05969847Rectal Cancer

DrugsCapecitabine, Oxaliplatin·Envafolimab·Folfox

池畔

Phase 2

Fuzhou

2023-08-15

Recruiting

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

NCT05698147Central Nervous System Lymphoma

DrugsSelinexor·Methotrexate·Rituximab

Tong Chen, MD

Phase 1/2

Hefei, Beijing, Fuzhou, Zhengzhou, Shanghai

2023-08-03

Recruiting

Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

NCT06101888Aortic Regurgitation

Peijia Medical Technology (Suzhou) Co., Ltd.

Not applicable

116

Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha

2023-08-01

Active, closed

Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)

NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer

DrugsCadonilimab·Gemcitabine·Cisplatin

Sun Yat-sen University

Phase 3

490

Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning

2023-08-01

Active, closed

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

NCT06044350Optic Neuromyelitis Spectrum Disease

DrugBAT4406F

Bio-Thera Solutions

Phase 2

162

Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou

2023-08-01

Recruiting

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

NCT05624099Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms

DrugCamrelizumab

Fujian Cancer Hospital

Phase 2

Fuzhou

2023-08-01

Active, closed

Effects of Shanyu Pill in Older Adults With Sarcopenia

NCT05919368Sarcopenia

Fujian University of Traditional Chinese Medicine

Not applicable

192

Fuzhou, Guangzhou

2023-07-17

Not yet open

Association of Osmotic Drugs With Clinical Outcomes in Acute Large Hemispheric Infarction

NCT05914272Stroke

Nanfang Hospital, Southern Medical University

Observational

2,592

Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang

2023-07-01

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou

2023-06-28

Recruiting

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

NCT05909332Breast Cancer, Triple Negative Breast Cancer

Fudan University

Phase 3

764

Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang

2023-06-20

Recruiting

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

NCT05837897Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

408

Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou

2023-06-16

Recruiting

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

NCT05913089Non Small Cell Lung Cancer

DrugsAnlotinib hydrochloride·Benmelstobart

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin

2023-06-14

Recruiting

Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy

NCT05892354Locally Advanced Nasopharyngeal Carcinoma

First Affiliated Hospital of Guangxi Medical University

Not applicable

190

Fuzhou, Guangzhou, Huizhou, Guilin, Liuzhou, Nanning, Wuzhou, Yulin

2023-06-12

Recruiting

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

NCT05303519Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3

DrugSafusidenib

Nuvation Bio Inc.

Phase 3

365

Beijing, Fuzhou, Guangzhou, Changsha, Shanghai, Chengdu

2023-06-05

Recruiting

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

NCT05891093Breast Cancer

DrugsFluzoparib·Tamoxifen·Exemestane·Anastrozole

Fudan University

Phase 3

766

Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang

2023-06-01

Recruiting

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

NCT06441110Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study

DrugsBacillus Calmette-Guerin·Tislelizumab

Fujian Medical University Union Hospital

Phase 3

Fuzhou

2023-06-01

Active, closed

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

NCT05740566Small Cell Lung Cancer (SCLC)

DrugsAmrubicin·Lurbinectedin·Tarlatamab·Topotecan

Amgen

Phase 3

509

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin

2023-05-31

By invitation

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

NCT06186804cGvHD

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 2

Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou

2023-05-30

Active, closed

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

NCT05879055Neuroendocrine Neoplasm

DrugsPumitamig·Folfox

Biotheus Inc.

Phase 2

Chongqing, Fuzhou, Harbin, Zhengzhou, Jingzhou, Wuhan, Changsha, Yongzhou

2023-05-17

Recruiting

LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer

NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer

Zhejiang University

Not applicable

568

Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha

2023-05-14

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

NCT05699655Immunotherapy Gastrict Cancer

DrugsTeysuno·Apatinib·Tislelizumab·Oxaliplatin

Fujian Cancer Hospital

Phase 2/3

130

Fuzhou

2023-05-10

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

NCT05862337Hepatocellular Carcinoma

DrugAnlotinib hydrochloride , Penpulimab

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

480

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning

2023-05-10

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou

2023-05-08

Active, closed

A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors

NCT05773820Advanced Solid Tumors

DrugWJB001

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Fuxin, Shenyang

2023-05-05

Recruiting

A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors

NCT05938309Gastrointestinal Stromal Tumors

Fujian Medical University

Observational

194

Fuzhou

2023-05-01

Not yet open

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

NCT05767892Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsIvonescimab·Pemetrexed

Suzhou Puhe Pharmaceutical Technology Co., LTD

Phase 3

350

Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou

2023-05-01

Recruiting

Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy

NCT03734952Radiation Oncology

Fujian Medical University Union Hospital

Not applicable

537

Fuzhou

2023-05-01

Recruiting

Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy

NCT05845372Acute Ischemic Stroke

Nanfang Hospital, Southern Medical University

Observational

2,592

Fuzhou, Dongguan, Guangzhou, Heyuan, Huizhou, Haikou, Changsha, Hengyang

2023-05-01

Active, closed

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 3

Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan

2023-04-27

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai

2023-04-24

Recruiting

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

NCT05744687Locally Advanced or Metastatic Breast Cancer

DrugSPH4336

Shanghai Pharmaceuticals Holding Co., Ltd

Phase 2/3

374

Fuzhou, Guangzhou, Guiyang, Anyang, Luoyang, Pingxiang, Changchun, Yinchuan

2023-04-24

Active, closed

A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)

NCT05816252Non-small Cell Lung Cancer

DrugsSacituzumab tirumotecan·Osimertinib·Carboplatin·Pembrolizumab

Klus Pharma Inc.

Phase 2

356

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2023-04-19

Active, closed

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

NCT05707377Primary Membranous Nephropathy

DrugsTacrolimus·Zanubrutinib

BeOne Medicines

Phase 2/3

178

Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang

2023-04-17

Active, closed

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

NCT05126719Recurrent or Metastatic Nasopharyngeal Carcinoma

DrugsBecotatug Vedotin·Docetaxel·Capecitabine

Lepu Biopharma Co., Ltd.

Phase 2

238

Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan

2023-04-06

Active, closed

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2

999

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou

2023-04-03

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2023-03-29

Recruiting

A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors

NCT05718895Advanced/Metastatic Solid Tumors

DrugATG-022

Antengene Biologics Limited

Phase 1

156

Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai

2023-03-27

Recruiting

Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

NCT06050980NSCLC

Haisco Pharmaceutical Group Co., Ltd.

Phase 1

220

Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha

2023-03-27

Recruiting

PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients

NCT05704166Acute Lung Injury, Prevention

Fujian Medical University Union Hospital

Phase 2

214

Fuzhou

2023-03-16

Recruiting

A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients

NCT06010342Solid Tumor

Teligene US

Phase 2

Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha

2023-03-16

Active, closed

Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

NCT05744427Advanced Solid Tumor

DrugJSKN003

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2

725

Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan

2023-03-15

Active, closed

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

DrugsMirvetuximab Soravtansine·Bevacizumab

AbbVie

Phase 3

520

Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan

2023-03-15

Active, closed

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

NCT05735496Advanced Cancer

DrugTQB2102

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

219

Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an

2023-03-09

Recruiting

The Study of ICP-248 in Patients With Mature B-cell Malignancies

NCT05728658Hematological Malignancies

DrugsICP-248·Orelabrutinib·Rituximab

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 1

191

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou

2023-03-09

Recruiting

OH2 Injection in Melanoma

NCT05868707Melanoma

DrugOH2

Binhui Biopharmaceutical Co., Ltd.

Phase 3

340

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin

2023-03-08

Active, closed

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

NCT05652894Metastatic Colorectal Cancer

DrugPucotenlimab

Taizhou Hanzhong biomedical co. LTD

Phase 3

190

Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou

2023-02-28

Active, closed

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

NCT05716087Mantle Cell Lymphoma (MCL)

DrugRocbrutinib

Guangzhou Lupeng Pharmaceutical Company LTD.

Phase 2

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou

2023-02-21

Recruiting

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

NCT05319639Gastric Cancer Stage IV

DrugsLevo-Leucovorin·Irinotecan·Adrucil·Tislelizumab

Fujian Cancer Hospital

Phase 1/2

Fuzhou

2023-02-16

Active, closed

Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC

NCT05557838Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

214

Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan

2023-02-15

Active, closed

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015Metastatic Non-small Cell Lung Cancer

DrugsPegylated filgrastim·Pembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol

Merck Sharp & Dohme LLC

Phase 3

377

Hefei, Beijing, Wanzhou, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Wuhan

2023-02-14

Active, closed

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

NCT05673785Lymphoma

DrugsBrentuximab Vedotin·Doxorubicin·Prednisone·Cyclophosphamide

Takeda

Phase 2

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei

2023-02-10

Active, closed

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866Non-small Cell Lung Cancer

DrugOsimertinib

AstraZeneca

Phase 2

Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou

2023-02-09

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan

2023-02-08

Active, closed

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

NCT05609968Carcinoma, Non-Small-Cell Lung

DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

614

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin

2023-02-06

Recruiting

Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumonia.

NCT07086391Carbapenem-Resistant Enterobacteriaceae Infection, Pneumonia - Bacterial

Fujian Medical University Union Hospital

Observational

144

Fuzhou

2023-02-01

Recruiting

Real-world Study Optimizing Nucleotide-analogues

NCT05937178Hepatitis B, Chronic

Huashan Hospital

Observational

20,000

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Nanning, Guiyang

2023-01-31

Active, closed

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

NCT05609370Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

DrugsFluoropyrimidine·Bevacizumab biosimilar·Tislelizumab·Bevacizumab

BeiGene

Phase 1/2

113

Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou

2023-01-29

Active, closed

The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection（BROAD）

NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases

Permed Biomedical Engineering Co., Ltd

Not applicable

259

Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang

2023-01-18

Active, closed

ABTECT - Maintenance

NCT05535946Ulcerative Colitis

DrugObefazimod

Abivax S.A.

Phase 3

1,116

Wuhu, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Shenyang

2023-01-16

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDato-DXd·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Beijing, Beijing Sheng, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou

2023-01-11

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong

2023-01-10

Active, closed

A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.

NCT05661955Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma, Non-mucosal Melanoma

DrugTislelizumab

BeiGene

Phase 1/2

113

Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha

2023-01-09

Active, closed

Adult Spinal Muscular Atrophy (SMA) China Registry

NCT05618379Muscular Atrophy, Spinal

Biogen

Observational

200

Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Nanchang

2023-01-06

Recruiting

3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer

NCT06161207Gastric Cancer, Surgery

Fujian Medical University

Phase 3

702

Fuzhou

2023-01-03

Recruiting

Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics

NCT05722275Gastric Cancer, Peritoneal Metastases

Chinese Academy of Sciences

Observational

400

Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang

2023-01-01

Recruiting

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

NCT06277024Overall Response Rate

Fujian Medical University

Not applicable

Fuzhou

2023-01-01

Active, closed

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

NCT05653752Non Small Cell Lung Cancer, Breast Cancer

DrugYL202

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

Fuzhou, Changsha, Changchun, Hangzhou, Taizhou

2022-12-20

Active, closed

A Study of Daratumumab

NCT05438043Multiple Myeloma

DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

214

Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Suzhou

2022-12-15

Active, closed

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988Non-small Cell Lung Cancer

DrugsSunvozertinib·Pemetrexed·Carboplatin

Dizal Pharmaceuticals

Phase 3

324

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin

2022-12-13

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2022-11-28

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou, Jinan, Qingdao

2022-11-21

Recruiting

A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

NCT05678270Intrahepatic Cholangiocarcinoma (ICC)

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2

Hefei, Beijing, Fujian, Fuzhou, Foshan, Guangzhou, Shijiazhuang, Harbin

2022-11-15

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Beijing, Fuzhou, Guangzhou, Wuhan, Nanjing, Suzhou, Changchun, Shanghai

2022-11-10

Active, closed

Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

NCT05486104Moderate to Severe Ulcerative Colitis

DrugMufemilast

Ganzhou Hemay Pharmaceutical Co., Ltd

Phase 2

Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang

2022-11-08

Not yet open

Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

NCT05610332Locally Advanced Gastric Cancer

DrugCamrelizumab

Fujian Medical University

Phase 3

216

Fuzhou

2022-11-01

Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05458219Locally Advanced Unresectable or Metastatic Solid Tumors

DrugsMFOLFOX·IBI343

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1

470

Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha

2022-10-26

Active, closed

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma

DrugSonrotoclax

BeiGene

Phase 2

100

Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan

2022-10-25

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Herceptin·Erbitux·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Fuzhou, Lanzhou, Guangzhou, Meizhou, Haikou, Chengde, Tangshan, Harbin

2022-10-24

Active, closed

LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB

NCT05572957Non-ischemic Cardiomyopathy, Heart Failure, Left Bundle-Branch Block

DrugGDMT

The First Affiliated Hospital with Nanjing Medical University

Not applicable

Beijing, Fuzhou, Nanjing, Dalian, Chengdu, Wenzhou

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Beijing, Changchun, Changsha, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou

2022-10-13

Active, closed

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

NCT06166836Solid Tumor

DrugIN10018

InxMed (Shanghai) Co., Ltd.

Phase 1/2

140

Hangzhou, Bengbu, Changsha, Fuzhou, Ganzhou, Nanjing, Wuhan, Xuzhou

2022-10-12

Active, closed

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237Non-small Cell Lung Cancer

DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed

Gilead Sciences

Phase 3

1,021

Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan

2022-10-12

Recruiting

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns

NCT06551220Metastatic Breast Cancer

DrugTrastuzumab deruxtecan

Sun Yat-sen University

Observational

800

Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan

2022-10-10

Recruiting

Deeper Intubation Make Effects on Cervical Esophageal ESD

NCT06420258Carcinoma in Situ of Cervical Part of Esophagus

Fujian Provincial Hospital

Phase 4

Fuzhou

2022-10-01

Recruiting

Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtworks

NCT05230017Anti Phospholipid Syndrome

Peking Union Medical College Hospital

Observational

2,000

Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Hohhot, Nanjing, Nanchang

2022-10-01

Active, closed

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT05535933Warm Antibody Autoimmune Hemolytic Anemia

Hutchmed

Phase 2/3

111

Fuyang, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Guilin, Haikou

2022-09-30

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

NCT05503264NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis

DrugSatralizumab

Hoffmann-La Roche

Phase 3

122

Beijing, Chengdu, Fuzhou, Jining, Shanghai, Wenzhou

2022-09-27

Active, closed

Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma

NCT07920757Extranodal NK/T-cell Lymphoma, Nasal Type

Fujian Medical University Union Hospital

Observational

Fuzhou

2022-09-27

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Beijing, Changchun, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Jinan

2022-09-23

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha

2022-09-20

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang

2022-09-13

Recruiting

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

NCT05536505MRD

Guangdong Association of Clinical Trials

Phase 2

180

Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei

2022-09-13

Active, closed

Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

NCT05471843Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma

DrugSonrotoclax

BeOne Medicines

Phase 1/2

125

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Zhengzhou, Wuhan

2022-09-05

Not yet open

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

NCT05524974Locally Advanced Gastric Cancer

DrugsApatinib Mesylate·Camrelizumab·Nab-paclitaxel·Oxaliplatin

Fujian Medical University

Phase 2

203

Fuzhou

2022-09-01

Active, closed

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

NCT05459844Neuroendocrine Tumors

DrugsLutetium[177Lu] Oxodotreotide·Octreotide·Octreotide LAR

Sinotau Pharmaceutical Group

Phase 3

196

Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun

2022-08-31

Recruiting

China HeadAche DIsorders RegiStry

NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache

DrugsErenumab·Eptinezumab

Beijing Tiantan Hospital

Observational

10,000

Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen

2022-08-29

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang

2022-08-22

Recruiting

A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma

NCT05409482Hepatocellular Carcinoma

Meng Chao Hepatobiliary Hospital of Fujian Medical University

Observational

300

Fuzhou

2022-08-20

Recruiting

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors

NCT05461768Breast Cancer, Locally Advanced or Metastatic Solid Tumor

DrugT-Bren

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 1

348

Fuzhou, Dongguan, Guangdong, Zhengzhou, Wuhan, Jinan, Hangzhou

2022-08-09

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou

2022-08-03

Recruiting

China HEalthy Aging and Dementia Study (HEAD)

NCT07912710Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD)

Fudan University

Observational

20,000

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan

2022-08-01

Recruiting

Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer

NCT03466424Radiation Oncology, Rectal Cancer

Fujian Medical University Union Hospital

Observational

Fuzhou

2022-08-01

Active, closed

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

NCT05457257Metastatic Castration-resistant Prostate Cancer

DrugsZytiga·Xtandi·Abiraterone acetate·Enzalutamide

AstraZeneca

Phase 4

Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2022-07-29

Active, closed

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

NCT05502393Advanced Solid Tumors

DrugsJS107·Toripalimab·Capecitabine·Oxaliplatin

Shanghai Junshi Bioscience Co., Ltd.

Phase 1

133

Chizhou, Fuzhou, Wuwei, Guangzhou, Meizhou, Shijiazhuang, Wuhan, Harbin

2022-07-26

Active, closed

Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)

NCT05511792Aortic Stenosis With Bicuspid Valve

Second Affiliated Hospital, Zhejiang University, School of Medicine

Not applicable

206

Fuzhou, Xiamen, Lanzhou, Guangzhou, Yulin, Zhengzhou, Changsha, Nanchang

2022-07-20

Active, closed

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

NCT05438329Advanced Solid Tumor

DrugsDB-1305/BNT325·Pumitamig

DualityBio Inc.

Phase 1/2

1,123

Bengbu, Hefei, Fuzhou, Lanzhou, Dongguan, Guangzhou, Guigang, Nanning

2022-07-19

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsPhesgo·Giredestrant·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Fuzhou, Hangzhou

2022-07-18

Active, closed

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

NCT05460273Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 1/2

119

Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou

2022-07-11

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Beijing, Changchun, Changsha, Chengdu, Chibi, Fuzhou, Guangzhou, Haidian

2022-07-08

Active, closed

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

NCT05365178HR-positive, HER2-negative Breast Neoplasms

DrugsTQB3616·Fulvestrant

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

432

Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei, Guangzhou

2022-07-01

Active, closed

TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

NCT05461339Neovascular Age-related Macular Degeneration

DrugsLucentis·Ranibizumab

BioDlink Biopharm Co., Ltd.

Phase 3

488

Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen

2022-06-28

Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

NCT05405595Advanced/Metastatic Solid Tumors

DrugsADG126·Keytruda·Pembrolizumab

Adagene Inc

Phase 1/2

186

Fuzhou, Guangzhou, Hong Kong

2022-06-15

Active, closed

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

NCT05047250Non-Small Cell Lung Cancer

DrugsTecentriq·Atezolizumab

Hoffmann-La Roche

Phase 3

Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing

2022-06-14

Recruiting

Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer

NCT05618821Gastric Cancer

Fujian Medical University

Phase 2

Fuzhou

2022-06-03

Active, closed

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

NCT05195632Non-Small Cell Lung Cancer

DrugsEncorafenib·Binimetinib

Pierre Fabre Medicament

Phase 2

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou

2022-06-02

Recruiting

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

NCT05515315Immunotherapy Esophagus Cancer

DrugsNedaplatin·Albumin paclitaxel·Tislelizumab

Fuzhou General Hospital

Phase 2

Fuzhou

2022-05-31

Active, closed

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

DrugLorlatinib

CStone Pharmaceuticals

Phase 2

Guangzhou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou

2022-05-27

Active, closed

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257Limited-Stage Small Cell Lung Cancer

DrugSerplulimab

Shanghai Henlius Biotech

Phase 3

511

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin

2022-05-17

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

146

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang

2022-05-06

Active, closed

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT05171647Non-Hodgkin Lymphoma

DrugsMosunetuzumab·Polatuzumab Vedotin·Tocilizumab·Rituximab

Hoffmann-La Roche

Phase 3

208

Chengdu, Fuzhou, Guangzhou, Tianjin, Wuhan, Zhengzhou

2022-04-25

Recruiting

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma

DrugsJAB-3312·Glecirasib

Allist Pharmaceuticals, Inc.

Phase 1/2

240

Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou

2022-04-14

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

NCT05239741Colorectal Neoplasms

DrugsLeucovorin·Irinotecan·Cetuximab·Adrucil

Merck Sharp & Dohme LLC

Phase 3

100

Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin

2022-04-02

Recruiting

Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).

NCT07561892Acute Myeloid Leukemia, Newly Diagnosed, Chemotherapy Effect

Fujian Medical University Union Hospital

Phase 4

100

Fuzhou

2022-04-01

Recruiting

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

NCT05340491Nasopharyngeal Carcinoma

DrugsJS001·Toripalimab

Sun Yat-sen University

Phase 3

212

Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning

2022-04-01

Active, closed

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab·Lenvatinib

AstraZeneca

Phase 3

760

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou

2022-03-28

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846Non Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab vedotin·Docetaxel

AbbVie

Phase 3

768

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang

2022-03-25

Active, closed

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

NCT05224141Small Cell Lung Carcinoma

DrugsPembrolizumab/Vibostolimab·Tecentriq·Paraplatin·Etoposide

Merck Sharp & Dohme LLC

Phase 3

460

Hefei, Beijing, Fuzhou, Harbin, Zhengzhou, Wuhan, Changsha, Suzhou

2022-03-24

By invitation

A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

NCT06707922Chronic Hepatitis B

DrugsTenofovir alafenamide fumarate·Peginterferon α-2b

Xiamen Amoytop Biotech Co., Ltd.

Not applicable

350

Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Guanzhou, Harbin, Hefei

2022-03-18

Active, closed

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

NCT05239728Carcinoma, Renal Cell

DrugsBelzutifan·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

1,800

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan

2022-03-15

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou

2022-03-10

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

NCT05201248B-Cell Non-Hodgkin Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 1/2

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Xuzhou

2022-03-10

Recruiting

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781Multiple Myeloma

DrugCilta-cel

Janssen Research & Development, LLC

Phase 4

295

Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

2022-03-09

Recruiting

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

NCT05112991Advanced Endometrial Cancer

DrugsEnvafolimab·Lenvatinib

3D Medicines (Sichuan) Co., Ltd.

Phase 2

108

Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yueyang

2022-03-04

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin

2022-02-21

Not yet open

the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer

NCT05235932Gastric Cancer, Robotic Gastrectomy

Fujian Medical University

Not applicable

570

Fuzhou

2022-02-20

Active, closed

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

NCT04851613Breast Cancer

DrugFulvestrant

Laekna Limited

Phase 3

256

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan

2022-02-18

Active, closed

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

NCT05180734Gastric or Esophagogastric Junction Adenocarcinoma

Shanghai Junshi Bioscience Co., Ltd.

Phase 3

878

Bengbu, Chizhou, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei

2022-02-10

By invitation

A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05076617Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

300

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming

2022-02-03

Active, closed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

NCT05173987Endometrial Neoplasms

DrugsTaxotere·Paraplatin·Taxol·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

280

Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang

2022-02-03

Active, closed

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

NCT05094336Advanced MTAP-null Solid Tumors

DrugsAnvumetostat·Docetaxel

Amgen

Phase 1/2

329

Chongqing, Fuzhou, Shanghai

2022-02-01

Active, closed

Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial

NCT05353816End-stage Heart Failure

Shenzhen Core Medical Technology CO.,LTD.

Not applicable

Beijing, Fuzhou, Guangzhou, Wuhan, Changsha, Zhengzhou, Nanjing, Suzhou

2022-01-26

Active, closed

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049Crohn Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

350

Bengbu, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou

2022-01-19

Recruiting

A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

NCT05851014Breast Cancer

DrugLetrozole

Genor Biopharma Co., Ltd.

Phase 3

350

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Wenzhou, Xiamen, Foshan

2022-01-14

Recruiting

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors

NCT05170958Advanced Solid Tumor

DrugLBL-024

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2

396

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning

2022-01-06

Active, closed

A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

NCT05114759Advanced Solid Tumors

DrugSHR-A2009

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

176

Chongqicun, Fuzhou, Guangzhou, Changsha, Nanchang, Changchun, Jinan, Xi’an

2022-01-04

Recruiting

Validation of CAGIB Score for In-hospital Mortality of Cirrhotic Patients With Acute Gastrointestinal Bleeding

NCT04662918GastroIntestinal Bleeding

Xingshun Qi

Observational

3,000

Beijing, Fuzhou, Wuhan, Nanchang, Dalian, Shenyang, Xi'an, Jinan

2022-01-01

By invitation

CLIME-CJD: A Multimodal Study

NCT07589283Creutzfeldt-Jakob Disease (CJD) | Prion Disease

First Affiliated Hospital of Fujian Medical University

Observational

150

Fuzhou

2022-01-01

Active, closed

Lorlatinib Continuation Study

NCT05144997Non-Small-Cell Lung Cancer, NSCLC

DrugLorlatinib

Pfizer

Phase 4

Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou

2021-12-28

Active, closed

Crizotinib Continuation Clinical Study

NCT05160922NSCLC, ALCL, IMT

DrugCrizotinib

Pfizer

Phase 4

Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai

2021-12-27

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Beijing, Fuzhou, Guangzhou, Harbin, Changsha, Changchun, Xi'an, Jinan

2021-12-20

Recruiting

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT05067283Advanced Solid Tumors

DrugsCalderasib·Leucovorin·Cetuximab·Adrucil

Merck Sharp & Dohme LLC

Phase 1

830

Beijing, Fuzhou, Guangzhou, Wuhan, Changchun, Shanghai, Hangzhou

2021-12-17

Active, closed

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

NCT04954859Hepatitis B

DrugBepirovirsen

GlaxoSmithKline

Phase 2

366

Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Shanghai

2021-12-14

Active, closed

A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

NCT05070858Generalized Myasthenia Gravis

DrugsCemdisiran·Pozelimab

Regeneron Pharmaceuticals

Phase 3

288

Beijing, Fuzhou, Guangdong, Guangzhou, Shenzhen, Haikou, Wuhan, Changsha

2021-12-14

Active, closed

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

DrugsZirabev·Taxotere·Avastin·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

643

Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Zhanjiang, Nanning, Haikou

2021-12-13

Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173Carcinoma, Squamous Cell

DrugsJNJ-90301900·Erbitux·Cetuximab

Johnson & Johnson Enterprise Innovation Inc.

Phase 3

500

Bengbu, Changsha, Chengdu, Dongguan, Fuzhou, Guangzhou, Jinan, Linyi

2021-12-10

Recruiting

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

NCT05077904Stereotypical Prolonged Seizures

DrugStaccato alprazolam

UCB Biopharma SRL

Phase 3

350

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming

2021-12-07

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Beijing, Bengbu, Changsha, Changzhi, Changzhou, Chengdu, Fuzhou, Guangzhou

2021-12-02

Recruiting

Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.

NCT05284318Periprosthetic Joint Infection, Anti-Bacterial Agents

First Affiliated Hospital of Fujian Medical University

Observational

500

Fuzhou

2021-12-01

Active, closed

Pediatric Spinal Muscular Atrophy (SMA) China Registry

NCT05042921Muscular Atrophy, Spinal

Biogen

Observational

600

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning

2021-11-18

Active, closed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

NCT04940052Differentiated Thyroid Cancer (DTC)

DrugsDabrafenib·Trametinib

Novartis Pharmaceuticals

Phase 3

153

Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Xuzhou, Changchun, Chengdu

2021-11-15

Recruiting

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma

DrugsEnvafolimab·Sunitinib·Lenvatinib

3D Medicines (Sichuan) Co., Ltd.

Phase 1/2

170

Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin

2021-11-15

Active, closed

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

NCT05176002Esophageal Neoplasm, Immunotherapy, Radiotherapy

DrugCamrelizumab

Fujian Medical University Union Hospital

Phase 1/2

Fuzhou

2021-11-10

Active, closed

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsTrastuzumab deruxtecan·Pemetrexed·Cisplatin·Carboplatin

AstraZeneca

Phase 3

454

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan

2021-10-28

Recruiting

A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.

NCT07392736Solid Tumor

DrugsAL8326·Toripalimab

Advenchen Laboratories, LLC

Phase 1/2

228

Beijing, Hunan, Fuzhou, Shantou, Shaoguan, Guilin, Liuzhou, Nanning

2021-10-26

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

430

Beijing, Fuzhou, Harbin, Wuhan, Changsha, Nanjing, Taizhou, Jinan

2021-10-25

Active, closed

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239Neoplasms

DrugsEzabenlimab·Pembrolizumab

Boehringer Ingelheim

Phase 1

151

Bengbu, Changsha, Fuzhou, Guangzhou, Wuhan

2021-10-18

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Beijing, Changchun, Changshashi, Chaoyang District, Chengdu, Fuzhou, Guangzhou, Hangzhou

2021-10-14

Active, closed

Study of Sacituzumab Govitecan in Patients With Solid Tumor

NCT05119907Solid Tumor

DrugSacituzumab Govitecan

Gilead Sciences

Phase 2

Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanjing

2021-10-12

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing

2021-10-04

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan

2021-10-04

Active, closed

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136Primary Biliary Cholangitis, PBC

DrugVolixibat

Mirum Pharmaceuticals, Inc.

Phase 2

333

Fuzhou, Wuhan, Changchun, Hangzhou, Beijing

2021-09-22

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang

2021-09-20

Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

NCT04973605Relapsed/Refractory Multiple Myeloma

DrugsSonrotoclax·Carfilzomib·Pomalidomide·Daratumumab

BeOne Medicines

Phase 1/2

246

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan

2021-09-16

Recruiting

A Registered Cohort Study on Neurodegenerative Associated With Sleep Disorder.

NCT05524922Neurodegenerative Disorder

Fujian Medical University Union Hospital

Observational

500

Fuzhou

2021-09-01

Recruiting

A Registered Cohort Study on α-Synucleinopathy

NCT05527067α-synucleinopathy

Fujian Medical University Union Hospital

Observational

500

Fuzhou

2021-09-01

Active, closed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

NCT04964375Neoplasms

DrugABSK043

Abbisko Therapeutics Co, Ltd

Phase 1

102

Chongqing, Fuzhou, Ganzhou, Hangzhou, Harbin, Hefei, Mianyang, Nanjing

2021-08-31

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning

2021-08-19

Active, closed

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT04974398Nasopharyngeal Carcinoma

DrugsPenpulimab·Cisplatin/Carboplatin·Gemcitabine

Akeso

Phase 3

296

Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen

2021-08-16

By invitation

Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

NCT04762459Non-small Cell Lung Carcinoma

DrugsAlmonertinib·Pemetrexed·Cisplatin

Chinese Academy of Medical Sciences

Phase 3

606

Beijing, Changsha, Chendu, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2021-08-01

By invitation

Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)

NCT06101940Myotonic Dystrophy 1

Huashan Hospital

Observational

1,000

Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou

2021-08-01

Active, closed

Newly Diagnosed Glioblastoma

NCT04959500Glioblastoma

DrugsAnlotinib hydrochloride·Temozolomide

Sun Yat-sen University

Phase 2

150

Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai

2021-07-21

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

NCT04951622Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

199

Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan

2021-07-15

Recruiting

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer

DrugZongertinib

Boehringer Ingelheim

Phase 1

554

Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai

2021-07-02

Recruiting

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

NCT05292742Breast Cancer, Adjuvant Therapy

DrugsPertuzumab/Trastuzumab·Pyrotinib·Trastuzumab·Capecitabine

Fujian Medical University Union Hospital

Phase 2

206

Fuzhou

2021-07-02

Active, closed

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

NCT04629248Primary Membranous Nephropathy

DrugsDiphenhydramine·Acetaminophen·Tacrolimus·Methylprednisolone

Hoffmann-La Roche

Phase 3

142

Hangzhou, Beijing, Chengdu, Fuzhou, Guangzhou, Shanghai, Wuhan, Xi'an

2021-06-25

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Zhengzhou

2021-06-24

Recruiting

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast

DrugHuaier

Fudan University

Phase 4

1,072

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou

2021-06-18

Recruiting

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

NCT06754059HER2-positive Breast Cancer

DrugPyrotinib

zhangjie

Observational

Fuzhou

2021-06-01

Active, closed

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

NCT04854668Metastatic Colorectal Cancer

DrugsAnlotinib hydrochloride·Capecitabine·Oxaliplatin·Bevacizumab

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

748

Chizhou, Fuzhou, Hefei, Xuancheng, Beijing, Chongqing, Xiamen, Lanzhou

2021-05-27

Active, closed

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

NCT04704934Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsRamucirumab·Trastuzumab deruxtecan·Paclitaxel

Daiichi Sankyo

Phase 3

490

Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan

2021-05-21

Active, closed

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

NCT04770896Unresectable Hepatocellular Carcinoma

DrugsSorafenib·Tecentriq·Atezolizumab·Lenvatinib

Hoffmann-La Roche

Phase 3

557

Changsha, Fuzhou, Guangzhou, Hefei, Nanjing, Shanghai, Shenyang, Tianjin

2021-04-26

Active, closed

A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

NCT04649489Venous Thrombosis

DrugsAtezolizumab & Bevacizumab·Bevacizumab

Jia Fan

Phase 3

501

Shanghai, Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei

2021-04-19

Active, closed

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706Carcinoma, Renal Cell

DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda

Merck Sharp & Dohme LLC

Phase 3

1,688

Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou

2021-04-14

Recruiting

HANGZHOU Solution in Bicuspid AS Undergoing TAVR

NCT04722796Aortic Stenosis, Aortic Stenosis With Bicuspid Valve

Second Affiliated Hospital, Zhejiang University, School of Medicine

Not applicable

508

Bengbu, Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha

2021-04-12

Active, closed

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255Lymphoma, Mantle-Cell

DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib

Loxo Oncology, Inc.

Phase 3

500

Hefei, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Yichang

2021-04-08

Active, closed

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)

DrugFluzoparib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3

496

Shanghai, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang

2021-03-18

Active, closed

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

NCT04712643Hepatocellular Carcinoma

DrugsTecentriq·Avastin·Atezolizumab

Hoffmann-La Roche

Phase 3

342

Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou

2021-03-12

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1

304

Changchun, Chengdu, Fuzhou, Shandong, Shanghai, Zhengzhou

2021-03-09

Not yet open

Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT

NCT04215510Recurrent Nasopharyngeal Carcinoma

Eye & ENT Hospital of Fudan University

Phase 3

286

Fuzhou, Nanchang, Shanghai

2021-03-01

Not yet open

Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer

NCT04795063Gastric Cancer, Robotic Gastrectomy

Fujian Medical University

Not applicable

160

Fuzhou

2021-03-01

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang

2021-02-23

Recruiting

Safety and Efficacy of Stereotactic Aspiration Plus Urokinase in Deep Intracerebral Hemorrhage Evacuation

NCT04686877Treatment of Spontaneous Intracerebral Hemorrhage

First Affiliated Hospital of Fujian Medical University

Not applicable

400

Fuzhou

2021-01-31

Active, closed

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT04718883Mantle Cell Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2

Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou

2021-01-13

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Qingdao, Xi’an

2021-01-04

Active, closed

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

NCT04666272Melanoma

DrugsDabrafenib·Trametinib

Novartis Pharmaceuticals

Observational

Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing

2020-12-31

Active, closed

Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)

NCT04765605Type B Aortic Dissection

Hangzhou Endonom Medtech Co., Ltd.

Not applicable

120

Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei

2020-12-25

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Zirabev·Erbitux·Xeloda

Pfizer

Phase 3

841

Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing

2020-12-21

Active, closed

Atrasentan in Patients With IgA Nephropathy

NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy

DrugsAtrasentan·Zigakibart

Novartis Pharmaceuticals

Phase 3

404

Dongguan, Fuzhou, Baotou, Nanjing, Nantong, Shanghai, Chengdu, Ürümqi

2020-12-11

Active, closed

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204Small Cell Lung Cancer

DrugsOlaparib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

672

Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha

2020-12-08

Active, closed

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

1,600

Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin

2020-12-04

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsAdagrasib·Pembrolizumab

Mirati Therapeutics Inc.

Phase 2/3

626

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen

2020-12-02

Active, closed

Postoperative Thrombosis Prevention in Patients With CD

NCT04486859Cushing Disease, DVT, Pulmonary Embolism

Huashan Hospital

Not applicable

206

Fuzhou, Guangzhou, Wuhan, Shanghai, Chengdu, Ürümqi, Beijing

2020-12-01

Active, closed

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

NCT04639986Metastatic Breast Cancer

DrugsCapecitabine Product·Eribulin·Vinorelbine·Xeloda

Gilead Sciences

Phase 3

331

Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan

2020-11-23

Active, closed

Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer

NCT04593615Gastric Cancer, Surgery

Fujian Medical University

Not applicable

1,070

Fuzhou

2020-11-10

By invitation

The Efficacy of Sequential RT After Triple Therapy for uHCC

NCT07052448Hepatocellular Carcinoma

Fujian Provincial Hospital

Observational

Fuzhou

2020-11-01

Active, closed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsCT041 autologous CAR T-cell·Apatinib·Irinotecan

CARsgen Therapeutics Co., Ltd.

Phase 1/2

192

Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing

2020-10-23

Active, closed

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

NCT04464226Cancer

DrugDarolutamide

Bayer

Phase 3

774

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen

2020-10-20

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Anyang, Beijing, Bengbu, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou

2020-10-19

Active, closed

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Carcinoma, Non-Small-Cell Lung

DrugsAmivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

308

Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou

2020-10-13

Active, closed

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

DrugEfgartigimod PH20

argenx

Phase 2

229

Beijing, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Guanzhou, Guiyang

2020-09-18

Active, closed

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

NCT05602935Stomach Neoplasms, Digestive System Neoplasms, Neoplasms, Digestive System Diseases

DrugCamrelizumab

The Second Affiliated Hospital of Fujian Medical University

Phase 2

Fuzhou

2020-09-16

Recruiting

Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE

NCT05188872Positron-Emission Tomography

First Affiliated Hospital of Fujian Medical University

Not applicable

100

Fuzhou

2020-09-01

Recruiting

Thrombus Aspiration in STEMI Patients With High Thrombus Burden

NCT04212494ST-segment Elevation Myocardial Infarction (STEMI)

Guangdong Provincial People's Hospital

Not applicable

3,838

Fuzhou, Foshan, Guangzhou, Huizhou, Jiangmen, Kaiping, Maoming, Shantou

2020-08-30

Recruiting

68Ga-FAPI PET/CT in Patients With Various Types of Cancer

NCT04499365Tumor, Positron-Emission Tomography, Metastasis

First Affiliated Hospital of Fujian Medical University

Early Phase 1

500

Fuzhou

2020-08-15

Active, closed

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

NCT04495296Advanced Cancer

DrugsTST001·Nivolumab·Capecitabine·Oxaliplatin

Transcenta Therapeutics (Hangzhou) Co., Ltd.

Phase 1/2

320

Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guangxi, Haikou

2020-08-13

Active, closed

A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

NCT04344158Advanced Hepatocellular Carcinoma (HCC)

DrugAnlotinib hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

648

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei

2020-08-11

Recruiting

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

NCT04504526Lymphoma, Multiple Myeloma, Leukemia

Drug68Ga-Pentixafor

First Affiliated Hospital of Fujian Medical University

Early Phase 1

Fuzhou

2020-08-07

Active, closed

ASPIrin in Reducing Events in Dialysis ( ASPIRED )

NCT04381143CKD (Chronic Kidney Disease) Stage 5D

DrugAspirin

Guangdong Provincial People's Hospital

Phase 4

9,082

Fuzhou, Longyan, Lanzhou, Dongguan, Foshan, Guangzhou, Guanzhou, Heyuan

2020-07-30

Recruiting

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

NCT05551507Platinum-resistant Ovarian Cancer

DrugIN10018

InxMed (Shanghai) Co., Ltd.

Phase 1/2

150

Anyang, Beijing, Changsha, Fuzhou, Hangzhou, Tianjin, Zhengzhou

2020-07-27

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

Baoding, Beijing, Changchun, Changsha, Dalian, Foshan, Fuzhou, Guangzhou

2020-07-24

Active, closed

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Hormone-Sensitive Prostate Cancer

DrugsZytiga·Capivasertib·Abiraterone acetate

AstraZeneca

Phase 3

1,012

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang

2020-07-13

Active, closed

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

DrugsParaplatin·Taxol·Olaparib·Etoposide

Merck Sharp & Dohme LLC

Phase 3

870

Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha

2020-07-06

Active, closed

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

DrugTazemetostat

Epizyme, Inc.

Phase 3

599

Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun

2020-06-11

Active, closed

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

NCT04379635Non Small Cell Lung Cancer

DrugsPemetrexed·Tislelizumab·Paclitaxel·Cisplatin

BeiGene

Phase 3

453

Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou

2020-05-29

Active, closed

Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

NCT03932331Phase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia

DrugAcalabrutinib

AstraZeneca

Phase 1/2

105

Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Haikou, Hangzhou

2020-04-29

Active, closed

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

NCT03934567Lymphoma, Follicular

DrugAbexinostat

Xynomic Pharmaceuticals, Inc.

Phase 2

Beijing, Changchun, Chengdu, Dalian, Fuzhou, Guangzhou, Hainan, Hangzhou

2020-04-22

Active, closed

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

NCT04223856Urothelial Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Astellas Pharma Global Development, Inc.

Phase 3

886

Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2020-03-30

Recruiting

CADASIL Registry Study

NCT04310098Cadasil

Bin Cai

Observational

1,000

Fuzhou

2020-03-09

Recruiting

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

NCT03907826Recurrent Nasopharyngeal Carcinoma

DrugJS001

Sun Yat-sen University

Phase 3

212

Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning

2020-03-01

Active, closed

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma

DrugSacituzumab tirumotecan

Klus Pharma Inc.

Phase 1/2

1,410

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou

2020-02-28

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

NCT04906434Advanced Liver Cancer

DrugABSK-011

Abbisko Therapeutics Co, Ltd

Phase 1

200

Bengbu, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Weifang, Haerbin

2020-02-26

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Harbin, Zhengzhou

2020-02-11

Recruiting

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT03936153Diffuse Large B-cell Lymphoma (DLBCL)

DrugAbexinostat

Xynomic Pharmaceuticals, Inc.

Phase 2

170

Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou

2020-01-20

Active, closed

A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

NCT04170283B-cell Malignancies

DrugsZanubrutinib·Tislelizumab

BeOne Medicines

Phase 3

955

Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing

2020-01-16

Recruiting

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

NCT07209878Prostate Cancer (Adenocarcinoma)

DrugIlluccix

First Affiliated Hospital of Fujian Medical University

Phase 2/3

100

Fuzhou

2020-01-10

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

NCT06195228Advanced Thyroid Cancer Patients Who Received Target Therapy

DrugsPralsetinib·Larotrectinib·Selpercatinib·Entrectinib

Fudan University

Phase 4

800

Fuzhou, Zhengzhou, Wuhan, Hohhot, Shanghai, Shanxi, Hangzhou, Beijing

2020-01-01

Active, closed

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317Non-muscle Invasive Bladder Cancer

DrugsSasanlimab·Bacillus Calmette-Guerin

Pfizer

Phase 3

1,068

Hefei, Beijing, Fuzhou, Wuhan, Changsha, Nanjing, Nantong, Suzhou

2019-12-30

Active, closed

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

NCT04194775Hepatocellular Carcinoma

DrugLenvatinib

CStone Pharmaceuticals

Phase 3

534

Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning

2019-12-13

Recruiting

Cerebral Small Vessel Disease Registry Study

NCT04318119Cerebral Small Vessel Diseases

Bin Cai

Observational

3,000

Fuzhou

2019-11-18

Active, closed

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

NCT04025879Carcinoma, Non-Small-Cell Lung

DrugsOpdivo·Pemetrexed·Docetaxel·Nivolumab

Bristol-Myers Squibb

Phase 3

461

Beijing, Fuzhou, Hubei Sheng, Changsha, Shanghai, Chengdu, Hangzhou

2019-11-05

Active, closed

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04076059Metastatic Hormone Sensitive Prostate Cancer

DrugsXtandi·Enzalutamide

Astellas (Beijing) Pharmaceutical R&D Co., Ltd.

Phase 3

180

Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Nanchang, Shanghai

2019-09-11

Recruiting

A Registered Cohort Study on Brain Calcification

NCT04010201Brain Calcification

Wan-Jin Chen

Observational

2,000

Fuzhou

2019-08-25

Active, closed

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

DrugsBendamustine·Zanubrutinib·Rituximab

BeOne Medicines

Phase 3

510

Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha

2019-08-20

Active, closed

Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease

NCT03977129Primary Valvular Heart Disease With Comorbid Coronary Artery Disease, Planned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease

Ruijin Hospital

Not applicable

792

Hefei, Fuzhou, Zhengzhou, Changsha, Jinan, Qingdao, Shanghai, Tianjin

2019-08-04

Recruiting

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

NCT04270591C-Met Exon 14 Mutation

DrugGlumetinib

Haihe Biopharma Co., Ltd.

Phase 1/2

183

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Haikou, Harbin, Zhengzhou

2019-07-15

Active, closed

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel

Eisai Inc.

Phase 1/2

301

Beijing, Changchun, Fuzhou, Guangzhou, Jinan, Kunming, Shanghai, Shenzhen

2019-07-11

Active, closed

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

NCT03974022Non-Small Cell Lung Cancer

DrugSunvozertinib

Dizal Pharmaceuticals

Phase 1/2

315

Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou

2019-07-09

Recruiting

A Registered Cohort Study on Amyotrophic Lateral Sclerosis

NCT04008329Amyotrophic Lateral Sclerosis

First Affiliated Hospital of Fujian Medical University

Observational

2,000

Fuzhou

2019-07-05

Recruiting

A Registered Cohort Study on Charcot-Marie-Tooth Disease

NCT04010188Charcot-Marie-Tooth Disease

Ning Wang, MD., PhD.

Observational

500

Fuzhou

2019-07-01

Recruiting

A Registered Cohort Study on Spastic Paraplegia

NCT04006418Spastic Paraplegia

Wan-Jin Chen

Observational

500

Fuzhou

2019-07-01

Recruiting

A Registered Cohort Study on Duchenne Muscular Dystrophy

NCT04012671Duchenne Muscular Dystrophy

Ning Wang, MD., PhD.

Observational

2,000

Fuzhou

2019-07-01

Recruiting

A Registered Cohort Study on Wilson's Disease

NCT04012658Wilson's Disease

Wan-Jin Chen

Observational

2,000

Fuzhou

2019-07-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou?page=2

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,040 of those studies with a site in Fuzhou.

How many clinical trials are recruiting in Fuzhou?

611 of the 1,040 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 117 have not yet opened recruitment, 289 are active but closed to new participants, and 23 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.